Function of secreted PLA2 group X in eosinophil biology

分泌型 PLA2 X 组在嗜酸性粒细胞生物学中的功能

基本信息

  • 批准号:
    8522225
  • 负责人:
  • 金额:
    $ 18.39万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-08-15 至 2015-05-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The synthesis of cysteinyl leukotrienes (CysLT)s by eosinophils plays an important role in the pathogenesis of asthma. We have discovered that secreted PLA2 group X (sPLA2-X) is involved in eosinophil CysLT synthesis, contradicting the long-held view that cytosolic PLA2¿ (cPLA2¿) is the only major PLA2 involved in CysLT formation in eosinophils. Our overall hypothesis is that sPLA2-X is upregulated in eosinophils during inflammation of the airways and plays an important role in CysLT formation by eosinophils. We have recently demonstrated that exogenous sPLA2-X initiates CysLT synthesis by human eosinophils through a mechanism that is dependent upon the enzymatic function of sPLA2-X, but also involves the activation of cPLA2¿, through p38 and c-Jun-terminal kinase (JNK). In preliminary data, we demonstrate that sPLA2-X is endogenously expressed in human eosinophils and that a highly selective inhibitor of sPLA2-X attenuates CysLT formation by fMLP-stimulated eosinophils. In the first specific aim, we will examine the intracellular location of sPLA2-X in human eosinophils using confocal microscopy. We will determine if the expression of sPLA2-X in eosinophils is increased by IL-3, IL-5, GMCSF and other cytokines that "prime" eosinophils for activation as they enter the airways. In a translational portion of this study, we will determine if sPLA2-X expression is increased in eosinophils from patients with asthma. In the second specific aim, we will examine the function of sPLA2-X in eosinophils first through selective inhibitors of sPLA2-X and cPLA2¿, and then through lentiviral-mediated shRNA knockdown of sPLA2-X in the eosinophil-like cell line HL-60 clone-15. Since sPLA2-X can act within cells and after secretion, we will determine if sPLA2-X co-localizes with 5-lipoxygenase (5-LO) during activation, and if it is released during piecemeal degranulation, allowing the enzyme to act on the outer cell membrane. Finally, we will examine the potential function of sPLA2-X in cell-free eosinophil granules that act as secretion competent organelles infiltrating the airway tissues of patients with asthma. Establishing the important function of sPLA2-X in eosinophil CysLT formation will provide a strong rationale for this enzyme as a therapeutic target in asthma.
描述(由申请人提供):嗜酸性粒细胞合成半胱氨酰白三烯(CysLT)在哮喘的发病机制中起着重要作用。我们发现分泌型 PLA2 X 基团 (sPLA2-X) 参与嗜酸性粒细胞 CysLT 合成,这与长期以来认为胞质 PLA2¿ (cPLA2¿) 是参与嗜酸性粒细胞 CysLT 形成的唯一主要 PLA2 的观点相矛盾。我们的总体假设是,气道炎症期间,sPLA2-X 在嗜酸性粒细胞中上调,并在嗜酸性粒细胞形成 CysLT 中发挥重要作用。我们最近证明,外源性 sPLA2-X 通过依赖于 sPLA2-X 酶功能的机制启动人嗜酸性粒细胞合成 CysLT,但也涉及通过 p38 和 c-Jun 末端激酶 (JNK) 激活 cPLA2¿。在初步数据中,我们证明 sPLA2-X 在人嗜酸性粒细胞中内源表达,并且 sPLA2-X 的高选择性抑制剂可减弱 fMLP 刺激的嗜酸性粒细胞形成 CysLT。在第一个具体目标中,我们将使用共聚焦显微镜检查人嗜酸性粒细胞中 sPLA2-X 的细胞内位置。我们将确定嗜酸性粒细胞中 sPLA2-X 的表达是否会因 IL-3、IL-5、GMCSF 和其他细胞因子的增加而增加,这些细胞因子在嗜酸性粒细胞进入气道时“启动”嗜酸性粒细胞的激活。在本研究的转化部分中,我们将确定哮喘患者的嗜酸性粒细胞中 sPLA2-X 的表达是否增加。在第二个具体目标中,我们将首先通过 sPLA2-X 和 cPLA2¿ 的选择性抑制剂来检查 sPLA2-X 在嗜酸性粒细胞中的功能,然后通过慢病毒介导的 shRNA 敲低嗜酸性粒细胞样细胞系 HL-60 clone-15 中的 sPLA2-X。由于 sPLA2-X 可以在细胞内和分泌后发挥作用,因此我们将确定 sPLA2-X 在激活过程中是否与 5-脂氧合酶 (5-LO) 共定位,以及它是否在分段脱颗粒过程中释放,从而允许酶作用于外细胞膜。最后,我们将检查 sPLA2-X 在无细胞嗜酸性粒细胞颗粒中的潜在功能,这些颗粒充当浸润哮喘患者气道组织的分泌细胞器。确定 sPLA2-X 在嗜酸性粒细胞 CysLT 形成中的重要功能将为该酶作为哮喘治疗靶点提供强有力的理论依据。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

TEAL S HALLSTRAND其他文献

TEAL S HALLSTRAND的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('TEAL S HALLSTRAND', 18)}}的其他基金

Origin and Function of Intra-epithelial Mast Cells in Asthma
哮喘上皮内肥大细胞的起源和功能
  • 批准号:
    10218653
  • 财政年份:
    2021
  • 资助金额:
    $ 18.39万
  • 项目类别:
Origin and Function of Intra-epithelial Mast Cells in Asthma
哮喘上皮内肥大细胞的起源和功能
  • 批准号:
    10599191
  • 财政年份:
    2021
  • 资助金额:
    $ 18.39万
  • 项目类别:
Origin and Function of Intra-epithelial Mast Cells in Asthma
哮喘上皮内肥大细胞的起源和功能
  • 批准号:
    10376361
  • 财政年份:
    2021
  • 资助金额:
    $ 18.39万
  • 项目类别:
Regulation of the Innate Immune Response by the Epithelium in Asthma
哮喘中上皮细胞对先天免疫反应的调节
  • 批准号:
    10160631
  • 财政年份:
    2020
  • 资助金额:
    $ 18.39万
  • 项目类别:
Regulation of the Innate Immune Response by the Epithelium in Asthma
哮喘中上皮细胞对先天免疫反应的调节
  • 批准号:
    10202415
  • 财政年份:
    2020
  • 资助金额:
    $ 18.39万
  • 项目类别:
Immunopathology of Indirect Airway Hyperresponsiveness in Asthma
哮喘间接气道高反应性的免疫病理学
  • 批准号:
    10369284
  • 财政年份:
    2017
  • 资助金额:
    $ 18.39万
  • 项目类别:
Immunopathology of Indirect Airway Hyperresponsiveness in Asthma
哮喘间接气道高反应性的免疫病理学
  • 批准号:
    10661502
  • 财政年份:
    2017
  • 资助金额:
    $ 18.39万
  • 项目类别:
Function of secreted PLA2 group X in eosinophil biology
分泌型 PLA2 X 组在嗜酸性粒细胞生物学中的功能
  • 批准号:
    8401088
  • 财政年份:
    2012
  • 资助金额:
    $ 18.39万
  • 项目类别:
Secretory Phospholipase A2s in Airway Pathophysiology
分泌性磷脂酶 A2 在气道病理生理学中的作用
  • 批准号:
    7459390
  • 财政年份:
    2008
  • 资助金额:
    $ 18.39万
  • 项目类别:
Secretory Phospholipase A2s in Airway Pathophysiology
分泌性磷脂酶 A2 在气道病理生理学中的作用
  • 批准号:
    9059757
  • 财政年份:
    2008
  • 资助金额:
    $ 18.39万
  • 项目类别:

相似海外基金

University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
  • 批准号:
    10073243
  • 财政年份:
    2024
  • 资助金额:
    $ 18.39万
  • 项目类别:
    Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    $ 18.39万
  • 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
  • 批准号:
    2339201
  • 财政年份:
    2024
  • 资助金额:
    $ 18.39万
  • 项目类别:
    Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
  • 批准号:
    MR/Y008693/1
  • 财政年份:
    2024
  • 资助金额:
    $ 18.39万
  • 项目类别:
    Research Grant
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
  • 批准号:
    10076445
  • 财政年份:
    2023
  • 资助金额:
    $ 18.39万
  • 项目类别:
    Grant for R&D
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
  • 批准号:
    23K14783
  • 财政年份:
    2023
  • 资助金额:
    $ 18.39万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
  • 批准号:
    23KJ0394
  • 财政年份:
    2023
  • 资助金额:
    $ 18.39万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Role of antibodies in hepatitis E virus infection
抗体在戊型肝炎病毒感染中的作用
  • 批准号:
    10639161
  • 财政年份:
    2023
  • 资助金额:
    $ 18.39万
  • 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
  • 批准号:
    10752441
  • 财政年份:
    2023
  • 资助金额:
    $ 18.39万
  • 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
  • 批准号:
    10867639
  • 财政年份:
    2023
  • 资助金额:
    $ 18.39万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了